In honor of Rare Disease Month, experts from Sanofi, Novartis and Definitive Healthcare will explore how the rare disease space has evolved and where it is heading in 2025.

This roundtable will provide key insights into how breaking down data silos, fostering collaboration, and focusing on rare diseases within the broader pharma ecosystem can accelerate the development of life-changing therapies.

Key discussion points will include:

• How Data Access Leads to Better Outcomes: Discussing how seamless access to integrated data—from clinical trials and real-world data- can enhance drug development, support better trial designs, and help pharma companies more efficiently address unmet medical needs in rare diseases.
• How to Improve Collaboration: Highlighting the critical need for collaboration between pharma companies, healthcare providers, academic institutions, and patient advocacy groups to drive more effective research and development and improve patient access to new therapies.
• The Future of Rare Disease in Pharma: Reflecting on how the increased focus on rare disease research, combined with better data access, will shape the future of drug development, personalized medicine, and patient care. Panelists will explore how the rare disease space has evolved and where it is heading in the coming years.

Speakers:

Alex Paragios, Regional Business Director (Sanofi)
Alex Paragios has been with Sanofi for 11+ years. In his role, he serves as the Regional Business Director – Northeast Pompe.

Brian Garino, Director, Advanced Analytics (Novartis)
Brian Garino is the Director, Advanced Analytics at Novartis. In his role, he leads predictive analytics practice designed to drive commercial acceleration via personal and digital touch optimization.

Evan Raggi, Principal
Evan Raggi brings 15+ years of data and analytics experience across cpg and healthcare companies. From start ups to fortune 100 companies, Evan has worked for some of the brightest and most innovative companies. At Definitive, Evan partners with our largest biopharma clients to help problem solve leveraging our entire portfolio of products and services.

Generative AI (GenAI) is revolutionizing the life sciences industry, with innovative proofs of concept (POCs) and use cases emerging rapidly. The opportunity now lies in determining how to advance these innovations to production, achieve scale, and create meaningful impact.

We’ve analyzed GenAI projects across the pharma and biotech industries and identified six key opportunity areas for teams to address in order to make AI a significant value driver within their organizations.

Join BeiGene and Beghou experts for concrete examples and actionable approaches for: 

• Kickstarting GenAI implementation and prioritizing use cases to build momentum
• Building a strong tech foundation with optimal data infrastructure
• Ensuring high data quality, privacy, and input accuracy 
  Monitoring and improving the model to ensure high performance and responsible AI principles
• Navigating change management and enabling ownership
• Moving GenAI forward while stabilizing what’s already been built 

The Pharmaceutical Industry is experiencing significant shifts across the value chain: from the increased focus on SDOH & health equity, to deep tech being embedded across touch-points; with new stakeholders & potential partnerships, emerging channels, the lasting pandemic effect on public distrust, compliance shifts and regulatory challenges; this is a time to Disrupt or Be Disrupted. We will share insights, action and provocations with relevance for Pharma companies exploring growth drivers, resilience through external changes and the application of AI, Data, Automation & Analytics.

Presenters:

• Sagar Shah, Head, Pharma Practice & Responsible AI, fractal.ai

Pharma companies are evolving to deliver a true omnichannel experience to their key customers. While it is crucial to develop both a personal and non-personal engagement plan for a multichannel strategy, a vital missing component is to connect next-best interactions and associated messaging across channels to create a harmonized omnichannel experience.

While a rep promotes his/her brand to an HCP, it is not common for the rep to discuss the brand’s digital presence, such as a published whitepaper or upcoming webinar to ensure prescribers are on-board digital channels. On the other end, brand marketers make considerable investments to engage customers using non-personal channels, but have no direct influence or control on the personal channel.

In this webinar series, we will review key challenges of interweaving personal and non-personal promotion to build an omnichannel customer engagement strategy. We will discuss ways to leverage AI/ML techniques to mine insights from complex and messy data and convert these insights to next-best-actions (NBAs) for sales professionals and other marketing channel providers. We will examine digital analytics KEY performance metrics and share an example of how these can be optimized for an email campaign for HCPs or patients. We will also showcase pharma industry-based case studies covering: customer journeys (across multiple digital channels, the journey analytics, and its impact on CX), and the power of AI/ML-based NBA suggestions in enhancing CX.

Part 2 will be focused on operationalizing omnichannel marketing.

Presenters:

• Devesh Verma and Geeta Padbidri, Axtria (Part 1)
• Robert Mozenter and Ilker Oruc, Axtria (Part 2)

Pharma companies are evolving to deliver a true omnichannel experience to their key customers. While it is crucial to develop both a personal and non-personal engagement plan for a multichannel strategy, a vital missing component is to connect next-best interactions and associated messaging across channels to create a harmonized omnichannel experience.

While a rep promotes his/her brand to an HCP, it is not common for the rep to discuss the brand’s digital presence, such as a published whitepaper or upcoming webinar to ensure prescribers are on-board digital channels. On the other end, brand marketers make considerable investments to engage customers using non-personal channels, but have no direct influence or control on the personal channel.

In this webinar series, we will review key challenges of interweaving personal and non-personal promotion to build an omnichannel customer engagement strategy. We will discuss ways to leverage AI/ML techniques to mine insights from complex and messy data and convert these insights to next-best-actions (NBAs) for sales professionals and other marketing channel providers. We will examine digital analytics KEY performance metrics and share an example of how these can be optimized for an email campaign for HCPs or patients. We will also showcase pharma industry-based case studies covering: customer journeys (across multiple digital channels, the journey analytics, and its impact on CX), and the power of AI/ML-based NBA suggestions in enhancing CX.

Part 1 will introduce a omnichannel customer engagement paradigm.

Presenters:

• Devesh Verma and Geeta Padbidri, Axtria (Part 1)
• Robert Mozenter and Ilker Oruc, Axtria (Part 2)